Your browser is no longer supported. Please, upgrade your browser.
BIIB Biogen Inc. daily Stock Chart
Biogen Inc.
IndexS&P 500 P/E20.11 EPS (ttm)16.31 Insider Own0.10% Shs Outstand211.40M Perf Week0.67%
Market Cap69.33B Forward P/E13.77 EPS next Y23.81 Insider Trans8.89% Shs Float210.86M Perf Month5.69%
Income3.49B PEG3.15 EPS next Q5.54 Inst Own91.60% Short Float1.61% Perf Quarter3.07%
Sales11.84B P/S5.86 EPS this Y10.30% Inst Trans0.81% Short Ratio2.71 Perf Half Y25.87%
Book/sh60.83 P/B5.39 EPS next Y7.97% ROA15.70% Target Price358.42 Perf Year24.07%
Cash/sh16.60 P/C19.76 EPS next 5Y6.39% ROE29.00% 52W Range244.28 - 348.84 Perf YTD25.55%
Dividend- P/FCF16.05 EPS past 5Y27.40% ROI21.00% 52W High-5.99% Beta0.73
Dividend %- Quick Ratio1.90 Sales past 5Y17.80% Gross Margin87.30% 52W Low34.25% ATR6.55
Employees7400 Current Ratio2.20 Sales Q/Q4.10% Oper. Margin40.20% RSI (14)55.04 Volatility2.28% 1.99%
OptionableYes Debt/Eq0.51 EPS Q/Q23.00% Profit Margin29.40% Rel Volume1.56 Prev Close323.55
ShortableYes LT Debt/Eq0.46 EarningsJan 23 BMO Payout0.00% Avg Volume1.26M Price327.94
Recom2.10 SMA203.08% SMA502.31% SMA20012.64% Volume1,957,046 Change1.36%
Oct-27-17Initiated Canaccord Genuity Hold $340
Oct-25-17Reiterated RBC Capital Mkts Sector Perform $315 → $313
Oct-24-17Initiated Guggenheim Buy $402
Oct-23-17Resumed Piper Jaffray Overweight $390
Oct-23-17Downgrade Citigroup Buy → Neutral
Oct-17-17Upgrade Stifel Hold → Buy $300 → $415
Oct-17-17Upgrade Mizuho Neutral → Buy $319 → $400
Oct-05-17Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-21-17Downgrade Raymond James Strong Buy → Mkt Perform
Sep-20-17Initiated SunTrust Buy $360
Sep-15-17Initiated RBC Capital Mkts Sector Perform $319
Jul-26-17Upgrade Goldman Neutral → Buy
Jul-11-17Resumed Jefferies Hold
Jun-23-17Initiated Deutsche Bank Buy $315
Jun-19-17Upgrade UBS Sell → Neutral $262 → $270
Mar-16-17Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-16-17Downgrade Leerink Partners Outperform → Mkt Perform
Mar-02-17Initiated Instinet Buy $345
Feb-07-17Upgrade Citigroup Neutral → Buy
Dec-29-16Reiterated Raymond James Strong Buy $375 → $386
Dec-15-17 11:15AM  Biotech Celgene May Rise 35% In 2018 Investopedia
Dec-14-17 03:15PM  Biogen, Ionis Sink As Competitor Plans Rival Drug To Spinraza Investor's Business Daily
Dec-13-17 07:31AM  5 Biotech Buyout Candidates for 2018 Motley Fool
Dec-12-17 03:00AM  Biogen Sees RS Rating Rise To 72 Investor's Business Daily
Dec-11-17 04:26PM  These 5 Top Stocks Are Near Buys In This Bullish Pattern: Action Plan Investor's Business Daily
Dec-08-17 08:04AM  See what the IHS Markit Score report has to say about Biogen Inc. Markit
Dec-07-17 04:01PM  Biogen to Present at the Guggenheim 5th Annual Healthcare Conference Business Wire
Dec-06-17 12:07PM  Biogen, Inc. Value Analysis (NASDAQ:BIIB) : December 6, 2017 Capital Cube
06:45AM  Biogen vet launches cancer drug startup with $50M from GV, others American City Business Journals
Dec-05-17 04:49PM  Biogen Seeks to Drive Neuroscience Innovation With CIO Hire The Wall Street Journal
04:31PM  Primecap Management Buys Alkermes Biopharma
12:23PM  ETFs with exposure to Biogen, Inc. : December 5, 2017 Capital Cube
07:50AM  Biogen, Inc. breached its 50 day moving average in a Bearish Manner : BIIB-US : December 5, 2017 Capital Cube
Dec-04-17 01:00PM  [$$] Icahn Protege's Big Biotech Buys: Biogen, Medicines
08:04AM  See what the IHS Markit Score report has to say about Biogen Inc. Markit
07:30AM  Biogen Appoints Mark Hernon as SVP, Chief Information Officer Business Wire
Dec-01-17 08:05AM  See what the IHS Markit Score report has to say about Biogen Inc. Markit
Nov-30-17 09:48AM  The Zacks Analyst Blog Highlights: Amazon, AbbVie, Biogen, McCormick and Hyatt Zacks
08:02AM  See what the IHS Markit Score report has to say about Biogen Inc. Markit
Nov-29-17 04:23PM  Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised) Zacks
04:12PM  Top Research Reports for Amazon, AbbVie & Biogen Zacks
08:08AM  Biotech Stock Roundup: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal Zacks
07:30AM  Recent Analysis Shows Aflac, Biogen, Oasis Petroleum, Twilio, Neothetics, and McDonald's Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-28-17 04:45PM  Biogen Acquires Worldwide License for Alkermes' MS Candidate Zacks
03:17PM  Biogen's Next Big Drug Is
08:00AM  Today's Research Reports on Stocks to Watch: Biogen and Teva Pharmaceutical ACCESSWIRE
Nov-27-17 04:21PM  Is Biogen's Multiple Sclerosis Franchise Getting A New Lease On Life? Investor's Business Daily
03:53PM  Biogen Inc. Buys Its Way Out of Competition Motley Fool
02:27PM  Biogen: If You Can't Beat 'em
12:39PM  TODAY'S CHARTS: Retailers pop on Cyber Monday; Time surges on Meredith deal Yahoo Finance
12:23PM  Biotechs Celgene, Biogen May Rally Through Yearend Investopedia
10:04AM  Biogen boosts multiple sclerosis holding with Alkermes license Reuters
09:30AM  Alkermes Jumps on License Deal With Biogen -- Biotech Movers
08:48AM  UPDATE: Alkermes shares rise 6% on Biogen multiple sclerosis drug partnership MarketWatch
08:05AM  See what the IHS Markit Score report has to say about Biogen Inc. Markit
07:28AM  Zacks Value Trader Highlights: General Electric, Macy's, Biogen, Chipotle and Exxon Mobil Zacks
07:00AM  Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis Business Wire
Nov-23-17 08:21AM  Biogen Inc (BIIB): Immense Growth Potential? Simply Wall St.
08:05AM  See what the IHS Markit Score report has to say about Biogen Inc. Markit
Nov-21-17 10:00AM  Biogen taps former Boston Scientific exec as next CFO American City Business Journals
07:30AM  Biogen Appoints Jeff Capello as Executive Vice President and Chief Financial Officer Business Wire
Nov-20-17 04:01PM  Biogen to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference Business Wire
08:05AM  See what the IHS Markit Score report has to say about Biogen Inc. Markit
Nov-18-17 09:37AM  Better Buy: Biogen Inc. vs. Gilead Sciences Motley Fool
Nov-17-17 10:12AM  Why Its Time to Put Pfizer Inc. Stock on Your Watchlist InvestorPlace
Nov-15-17 03:26PM  Steven Cohen's 6 Best Performing Stocks That Still Have Big Upside Benzinga
08:03AM  See what the IHS Markit Score report has to say about Biogen Inc. Markit
05:00AM  If An Alzheimer's Drug Succeeds, Could Our Health System Handle It? Forbes
Nov-14-17 03:44PM  Ionis Pharmaceuticals Inc. Sets Itself Up for Growth Motley Fool
02:08PM  Why Biotech Stocks Are Nearing a Rebound Investopedia
08:02AM  See what the IHS Markit Score report has to say about Biogen Inc. Markit
Nov-13-17 10:08AM  Which Will Pfizer Buy? Biogen or Bristol-Myers Squibb
Nov-11-17 07:21AM  Better Buy: Acadia Pharmaceuticals vs. Biogen Motley Fool
Nov-07-17 01:53PM  Is Biogen Inc (BIIB) Expensive For A Reason? A Look At The Intrinsic Value Simply Wall St.
09:46AM  ETFs with exposure to Biogen, Inc. : November 7, 2017 Capital Cube
Nov-06-17 03:00AM  Biogen Shows Rising Relative Strength; Still Shy Of Key Threshold Investor's Business Daily
Nov-02-17 04:30PM  Biogen Appoints Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation Business Wire
07:40AM  Earnings Review and Free Research Report: Biogens Adjusted EPS Surged 25.1% ACCESSWIRE
07:30AM  Biogen Presents New Data from Long-Term Extension of Phase 1b Study of Investigational Alzheimers Disease Treatment Aducanumab Business Wire
03:00AM  Biogen Sees IBD RS Rating Climb To 73 Investor's Business Daily
Nov-01-17 06:26PM  Is a Beat in Store for Ionis (IONS) This Earnings Season? Zacks
05:06PM  The New England Journal of Medicine Publishes First Phase 3 Study Results of SPINRAZA® for the Treatment of Spinal Muscular Atrophy Business Wire
08:00AM  Biotech Stocks Are Suddenly a Bargain Investopedia
Oct-31-17 03:53PM  Top Analyst Reports for Microsoft, Chevron & Intel Zacks
02:29PM  Ionis Down Big on Analyst Miss Motley Fool
03:00AM  Biogen Sees Relative Strength Rating Climb To 75 Investor's Business Daily
Oct-30-17 04:01PM  Biogen to Present at the Clinical Trials on Alzheimers Disease Conference Business Wire
09:01AM  International Markets Could Drive Spinraza Sales in 2017 Market Realist
07:32AM  Geographic Market Expansion to Boost Spinraza Sales in 2017 Market Realist
Oct-29-17 03:04PM  3 ETFs to Watch on Biotech Earnings Zacks
Oct-27-17 12:26PM  Spinraza Continues to See Improvement in Sales Metrics in 2017 Market Realist
11:07AM  Celgene and Biogen May Be Signalling A Biotech Bottom Investopedia
10:57AM  Spinraza Has Emerged as Key Growth Driver for Ionis in 2017 Market Realist
09:24AM  What Analysts Recommend for Ionis and Peers in October 2017 Market Realist
09:03AM  Analysts Recommendations for Biogen in October 2017 Market Realist
07:50AM  Biogen and Ionis Win Prestigious Prix Galien Award for SPINRAZA as Best Biotechnology Product Business Wire
07:37AM  Biogens Biosimilars and Interferons in 3Q17 Market Realist
Oct-26-17 05:55PM  How 3Q17 Shaped up for Tysabri, Fampyra, and Zinbryta Market Realist
04:36PM  A Look at Biogens Tecfidera in 3Q17 Market Realist
02:50PM  How Biogen Performed in 3Q17 Market Realist
10:21AM  ETFs with exposure to Biogen, Inc. : October 26, 2017 Capital Cube
10:06AM  Key Predictions for Q3 Earnings Reports of ABBV, MRK Zacks
09:07AM  Biogen, Inc. :BIIB-US: Earnings Analysis: Q3, 2017 By the Numbers : October 26, 2017 Capital Cube
08:04AM  See what the IHS Markit Score report has to say about Biogen Inc. Markit
07:20AM  Featured Company News - Viking Presents Positive Results From In Vivo Study of VK2809 in NASH at the Annual Meeting of AASLD ACCESSWIRE
Oct-25-17 07:01PM  Cramer's lightning round: There's no upside story for Kro... CNBC Videos
02:41PM  Biogen Inc Content With "Resilience" of Its Multiple Sclerosis Franchise Motley Fool
12:24PM  BMO: Biogen's Risks Quickly Becoming Priced In, But This May Not Be The Bottom Benzinga
12:24PM  Biogen: Let's Start All Over Again
08:07AM  Biotech Stock Roundup: Biogen Tops Q3 Earnings, Gilead's CAR T Drug Gets FDA Nod Zacks
08:01AM  What's Biogen's Big Risk? Motley Fool
01:00AM  Biogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis Business Wire
Oct-24-17 10:15PM  Edited Transcript of BIIB earnings conference call or presentation 24-Oct-17 12:30pm GMT Thomson Reuters StreetEvents
09:00PM  Ionis Pharmaceuticals Tumbles on Biogen's Miss: Buy or Sell? Motley Fool
05:01PM  Biogen Dives Despite Topping Views; Lilly, Novartis Beat Investor's Business Daily
04:10PM  Biogen Shares Hit After Poor U.S. Sales for Muscular Atrophy Treatment
01:00PM  Alexion: How Do You Spell Relief?
12:59PM  US STOCKS-Dow rallies on strong earnings from 3M, Caterpillar Reuters
12:53PM  Biogen (BIIB) Tops Q3 Earnings & Sales, Spinraza Sales Up Zacks
12:19PM  Why Ionis Pharmaceuticals Inc. Slipped This Morning Motley Fool
Biogen Inc., a biopharmaceutical company, discovers, develops, manufactures, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and other potential anti-CD20 therapies. The company's Phase III clinical trial products comprise GAZYVA for the treatment of front-line indolent non-hodgkin's lymphoma; and Aducanumab and E2609 for Alzheimer's disease. Its Phase II clinical trial products include BIIB074 for trigeminal neuralgia, lumbosacral radiculopathy, and erythromelalgia; BAN2401 for Alzheimer's disease; Opicinumab (anti-LINGO-1) for MS; TYSABRI for acute ischemic stroke; rAAV-XLRS for X-linked juvenile retinoschisis; BG00011 (STX-100) for idiopathic pulmonary fibrosis; and Dapirolizumab pegol and BIIB059 (Anti-BDCA02) for lupus. The company's Phase I clinical trial products comprise BIIB061 for MS; BIIB054 for Parkinson's disease; BIIB067 (IONIS-SOD1Rx) for amyotrophic lateral sclerosis; and BIIB068 (BTK Inhibitor) for autoimmune disease. It has collaboration agreements with AbbVie, Inc.; Acorda Therapeutics, Inc.; Applied Genetic Technologies Corporation; Eisai Co., Ltd.; Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and University of Pennsylvania. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DENNER ALEXANDER JDirectorNov 29Buy319.8410,0003,198,400413,858Nov 30 07:30 AM
DENNER ALEXANDER JDirectorNov 28Buy316.1220,0006,322,400403,858Nov 30 07:30 AM
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & SecJul 25Sale290.014,9741,442,51022,258Jul 26 04:22 PM
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & SecJul 19Sale285.007,7582,211,03027,232Jul 20 05:00 PM
Posner Brian SDirectorJun 09Sale256.311,084277,8406,330Jun 12 04:29 PM
Ehlers Michael DEVP, Research and DevelopmentJun 01Option Exercise0.001,25904,027Jun 05 04:38 PM
Vounatsos MichelChief Executive OfficerMay 02Option Exercise0.001,73604,663May 04 04:16 PM
Vounatsos MichelChief Executive OfficerMay 01Buy271.351,402380,4332,927May 02 04:18 PM
DENNER ALEXANDER JDirectorApr 27Buy278.5073,85820,569,476383,858May 01 05:47 PM
Clancy Paul JExecutive VP and CFOApr 25Sale290.009,8922,868,68010,813Apr 27 04:23 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratApr 03Sale274.081,981542,9527,060Apr 04 04:18 PM
Clancy Paul JExecutive VP and CFOMar 13Sale291.559,8912,883,72120,705Mar 14 07:32 PM
McKenzie PaulEVP Pharmaceutical Oper & TechMar 01Option Exercise0.004810718Mar 03 06:07 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratMar 01Sale290.07973282,2389,041Mar 03 06:02 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffFeb 28Option Exercise0.002,06409,237Mar 02 05:16 PM
DiPietro KennethEVP Human ResourcesFeb 28Option Exercise0.005,69608,260Mar 02 05:12 PM
Clancy Paul JExecutive VP and CFOFeb 28Option Exercise0.006,780031,948Mar 02 05:24 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 28Option Exercise0.004,785010,398Mar 02 05:22 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 28Option Exercise0.005,559036,024Mar 02 05:20 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 28Option Exercise0.0068104,508Mar 02 05:18 PM
Vounatsos MichelChief Executive OfficerFeb 27Buy285.391,333380,4251,434Mar 01 04:18 PM
PANGIA ROBERT WDirectorJan 09Option Exercise52.225,450284,59922,078Jan 10 04:15 PM
PANGIA ROBERT WDirectorJan 09Sale295.395,4501,609,87616,628Jan 10 04:15 PM